- Home
- LOMA vs ATAI Comparison
LOMA vs ATAI Comparison
Compare LOMA & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$10.10
HOLD
Current Price
$3.71
Company Overview
Basic Information| Metric | LOMA | ATAI |
|---|---|---|
| Founded | 1926 | 2018 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LOMA | ATAI |
|---|---|---|
| Price | $10.10 | $3.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $15.00 | ★ $15.29 |
| AVG Volume (30 Days) | 299.2K | ★ 4.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,000.00 |
| Revenue This Year | $22.92 | $955.84 |
| Revenue Next Year | $25.84 | N/A |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.04 | $1.15 |
| 52 Week High | $14.17 | $6.73 |
Technical Indicators
Market Signals| Indicator | LOMA | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 33.37 | 46.28 |
| Support Level | $7.26 | $3.42 |
| Resistance Level | $12.33 | $4.46 |
| Average True Range (ATR) | 0.53 | 0.29 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 12.93 | 25.67 |
Price Performance
Historical Comparison LOMA
ATAI
About LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.